These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35577136)

  • 1. Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations.
    Ortiz CE; Dourron HM; Sweat NW; Garcia-Romeu A; MacCarthy S; Anderson BT; Hendricks PS
    Neuropharmacology; 2022 Aug; 214():109127. PubMed ID: 35577136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of psilocybin and MDMA in the treatment of mental illness.
    Gill H; Gill B; Chen-Li D; El-Halabi S; Rodrigues NB; Cha DS; Lipsitz O; Lee Y; Rosenblat JD; Majeed A; Mansur RB; Nasri F; Ho R; McIntyre RS
    Expert Rev Neurother; 2020 Dec; 20(12):1263-1273. PubMed ID: 32954860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy.
    Mocanu V; Mackay L; Christie D; Argento E
    Subst Abuse Treat Prev Policy; 2022 May; 17(1):37. PubMed ID: 35568884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psilocybin occasioned mystical-type experiences.
    James E; Robertshaw TL; Hoskins M; Sessa B
    Hum Psychopharmacol; 2020 Sep; 35(5):e2742. PubMed ID: 32573835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psilocybin for Trauma-Related Disorders.
    Khan AJ; Bradley E; O'Donovan A; Woolley J
    Curr Top Behav Neurosci; 2022; 56():319-332. PubMed ID: 35711024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psilocybin-assisted psychotherapy for treatment-resistant depression: Which psychotherapy?
    Crowe M; Manuel J; Carlyle D; Lacey C
    Int J Ment Health Nurs; 2023 Dec; 32(6):1766-1772. PubMed ID: 37589380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psilocybin: A brief overview for psychiatric mental health nurse practitioners.
    Fradkin D
    Perspect Psychiatr Care; 2022 Jul; 58(3):1200-1203. PubMed ID: 34101846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do the therapeutic effects of psilocybin involve actions in the gut?
    Reed F; Foldi CJ
    Trends Pharmacol Sci; 2024 Feb; 45(2):107-117. PubMed ID: 38216431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin.
    Bogenschutz MP
    Curr Drug Abuse Rev; 2013 Mar; 6(1):17-29. PubMed ID: 23627783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psilocybin-assisted therapy for depression: How do we advance the field?
    Meikle SE; Liknaitzky P; Rossell SL; Ross M; Strauss N; Thomas N; Murray G; Williams M; Castle DJ
    Aust N Z J Psychiatry; 2020 Mar; 54(3):225-231. PubMed ID: 31752499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin.
    Carhart-Harris RL; Leech R; Williams TM; Erritzoe D; Abbasi N; Bargiotas T; Hobden P; Sharp DJ; Evans J; Feilding A; Wise RG; Nutt DJ
    Br J Psychiatry; 2012 Mar; 200(3):238-44. PubMed ID: 22282432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Policy in focus: Is psilocybin the next cannabis?
    Basky G
    CMAJ; 2021 Nov; 193(45):E1741-E1742. PubMed ID: 34782381
    [No Abstract]   [Full Text] [Related]  

  • 19. Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis.
    Crowe M; Manuel J; Carlyle D; Lacey C
    Int J Ment Health Nurs; 2023 Aug; 32(4):1025-1037. PubMed ID: 36779424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroimaging: a scanner, colourfully.
    Roiser JP; Rees G
    Curr Biol; 2012 Apr; 22(7):R231-3. PubMed ID: 22497939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.